Scynexis (SCYX) EBITDA Margin (2013 - 2026)
Scynexis' (SCYX) quarterly EBITDA Margin came in at 3308.51% in Q2 2026, down 260756.0% on a YoY basis from N/an in Q2 2025, and down 5963.56% quarter-over-quarter from 56.42% in Q4 2025.
Powered by 
Analysis
Scynexis (SCYX) EBITDA Margin (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported EBITDA Margin for 13 consecutive years, with 3308.51% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 260756.0% year-over-year to 3308.51%; the trailing twelve-month figure through Jun 2026 stood at 117.61% (up 100406.0% YoY), and the FY2025 full-year result was 78.03%, up 91282.0% from the prior year.
- EBITDA Margin eased to 3308.51% in Q2 2026 per SCYX's latest filing, from 56.42% in the prior quarter.
- Across five years, EBITDA Margin topped out at 88.63% in Q2 2023 and bottomed at 3350.19% in Q1 2025.
- Historically, EBITDA Margin has averaged 1371.84% across 5 years, with a median of 1255.03% in 2024.
- The widest YoY moves for EBITDA Margin: up 236744 bps in 2022, down 280649 bps in 2022.
- Over 5 years, EBITDA Margin stood at 1475.13% in 2022, then surged by 73 bps to 397.88% in 2023, then slumped by 107 bps to 824.26% in 2024, then jumped by 107 bps to 56.42% in 2025, then slumped by 5964 bps to 3308.51% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 3308.51%, 56.42%, and 2516.47% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -3,308.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,308.51% |
| Dec 31, 2025 | 56.42% |
| Sep 30, 2025 | -2,516.47% |
| Jun 30, 2025 | -700.95% |
| Mar 31, 2025 | -3,350.19% |
| Dec 31, 2024 | -824.26% |
| Sep 30, 2024 | -1,563.64% |
| Jun 30, 2024 | -1,255.03% |
| Mar 31, 2024 | -692.50% |
| Dec 31, 2023 | -397.88% |
| Sep 30, 2023 | -573.42% |
| Jun 30, 2023 | 88.63% |
| Mar 31, 2023 | -945.31% |
| Dec 31, 2022 | -1,475.13% |
| Sep 30, 2022 | -1,400.19% |
| Jun 30, 2022 | -1,643.08% |
| Mar 31, 2022 | -2,819.71% |
| Dec 31, 2021 | -3,734.84% |
| Sep 30, 2021 | -3,767.64% |
| Mar 31, 2021 | -13.23% |